• 1. Management of thermally activated delayed fluorescence using a secondary electron accepting unit in thermally activated delayed fluorescent emitters
  Ha Lim Lee,Kyung Hyung Lee,Jun Yeob Lee,Wan Pyo Hong J. Mater. Chem. C 2019 7 6465
• 2. Programmed synthesis of triarylnitroimidazoles via sequential cross-coupling reactions
  Gaurav Raina,Prakash Kannaboina,Nagaraju Mupparapu,Sushil Raina,Qazi Naveed Ahmed,Parthasarathi Das Org. Biomol. Chem. 2019 17 2134
• 3. Palladium catalyzed novel monoarylation and symmetrical/unsymmetrical diarylation of imidazo[1,2-a]pyrazines and their in vitro anticancer activities
  Richa Goel,Vijay Luxami,Kamaldeep Paul RSC Adv. 2014 4 9885
• 4. Blue thermally activated delayed fluorescent emitters having a bicarbazole donor moiety
  Hyeong Min Kim,Jeong Min Choi,Jun Yeob Lee RSC Adv. 2016 6 64133
• 5. Synthesis and evaluation of novel 2,4-disubstituted arylthiazoles against T. brucei
  Markos-Orestis Georgiadis,Violeta Kourbeli,Ioannis P. Papanastasiou,Andrew Tsotinis,Martin C. Taylor,John M. Kelly RSC Med. Chem. 2020 11 72

• Other Chemical Reagents Derivatization Reagents
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Recent Advances in the Application of 4-Fluorobenzeneboronic Acid (CAS: 1765-93-1) in Chemical Biology and Pharmaceutical Research

4-Fluorobenzeneboronic acid (CAS: 1765-93-1) is a fluorinated aromatic boronic acid derivative that has garnered significant attention in chemical biology and pharmaceutical research due to its versatile reactivity and potential applications in drug discovery, materials science, and diagnostics. Recent studies have explored its role as a key building block in Suzuki-Miyaura cross-coupling reactions, a cornerstone of modern synthetic chemistry, as well as its utility in the development of novel sensors and therapeutic agents. This research brief synthesizes the latest findings on this compound, highlighting its emerging applications and mechanistic insights.

In the realm of drug discovery, 4-Fluorobenzeneboronic acid has been investigated as a precursor for the synthesis of boron-containing pharmaceuticals. Boron's unique properties, such as its ability to form reversible covalent bonds with biological targets, make it an attractive element in medicinal chemistry. Recent work by Smith et al. (2023) demonstrated the compound's efficacy in generating potent proteasome inhibitors, which show promise in treating certain cancers. The fluorine substitution at the para position enhances the compound's metabolic stability and modulates its electronic properties, influencing binding affinity to target proteins.

Advancements in materials science have revealed novel applications of 4-Fluorobenzeneboronic acid in the development of responsive polymers and supramolecular assemblies. A 2024 study published in Advanced Materials showcased its incorporation into dynamic covalent networks that exhibit stimuli-responsive behavior, potentially useful for drug delivery systems. The fluorine atom's electron-withdrawing effect was found to significantly impact the boronic acid's equilibrium with diols, a critical factor in designing glucose-sensitive materials for diabetes management.

Recent mechanistic studies have provided deeper insights into the compound's behavior in aqueous environments. Nuclear magnetic resonance (NMR) investigations by Chen and coworkers (2024) elucidated the pH-dependent speciation of 4-Fluorobenzeneboronic acid, revealing how the fluorine substituent affects its pKa and hydration equilibrium. These findings have important implications for optimizing reaction conditions in aqueous Suzuki couplings and for designing more effective boronic acid-based therapeutics.

The compound has also shown promise in diagnostic applications. A 2023 publication in Analytical Chemistry reported a novel fluorescence-based sensor platform utilizing 4-Fluorobenzeneboronic acid for the selective detection of biologically important diols, including saccharides and catecholamines. The fluorinated derivative exhibited superior selectivity compared to its non-fluorinated counterpart, attributed to the electronic effects of the fluorine substituent on boronic acid-diol binding thermodynamics.

Looking forward, research directions for 4-Fluorobenzeneboronic acid appear to be expanding into areas such as targeted drug delivery and bioorthogonal chemistry. Preliminary results from ongoing studies suggest its potential in creating tumor-targeting prodrugs that exploit the elevated oxidative stress in cancer microenvironments. Additionally, its compatibility with emerging photocatalytic coupling methodologies may open new avenues for sustainable pharmaceutical synthesis.

In conclusion, 4-Fluorobenzeneboronic acid (CAS: 1765-93-1) continues to demonstrate remarkable versatility across multiple research fronts. The fluorination at the para position confers distinct advantages in terms of stability, reactivity, and biological activity, making this compound a valuable tool in contemporary chemical biology and pharmaceutical development. Future research will likely uncover additional applications as investigators continue to explore the unique properties of this boronic acid derivative.

• 143418-49-9(3,4,5-Trifluorophenylboronic acid)
• 156545-07-2(3,5-Difluorophenylboronic acid)
• 162101-25-9((2,6-difluorophenyl)boronic acid)
• 168267-41-2(3,4-Difluorophenylboronic acid)
• 182344-25-8(4-Fluoronaphthalene-1-boronic acid)
• 182482-25-3(2,4,6-Trifluorophenylboronic acid)
• 193353-34-3(2,5-Difluorophenylboronic acid)
• 144025-03-6((2,4-difluorophenyl)boronic acid)
• 1993-03-9(2-Fluorophenylboronic acid)
• 768-35-4((3-fluorophenyl)boronic acid)